May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]
May 12, 2022 — Somehow this doesn’t seem right. The list price for for a month’s supply of semaglutide when it’s for diabetes is $892. No matter whether you need a dose of 1 mg, or the new high dose of 2 mg, the price is the same. It goes under the brand name of Ozempic and comes from […]
May 6, 2022 — As we prepare to put a bow on ECO2022, it’s plain that some things in obesity are changing rapidly. But others are not. Though the reality of coping with it is still far from ideal, the options are getting much better. The scientific understanding of it has grown sharper, but messages to the public aren’t […]
April 28, 2022 — Make no mistake. The competition to deliver better therapies for obesity is heating up in an impressive way. This morning, Eli Lilly released topline results for their first phase three trial of tirzepatide in obesity. One word sums up the reaction from top clinical scientists in obesity: “Wow!” Jeff Emmick is the vice president of […]
March 20, 2022 — “Focusing on cancer, focusing on obesity, focusing on diabetes, a whole range of diseases … we’re going to make significant breakthroughs.” This in a nutshell is the aspiration for ARPA-H, as voiced by President Joe Biden. It is a new agency with a billion dollars of funding for the next three years, passed in a bipartisan […]
March 15, 2022 — The pandemic isn’t done with us yet. Cases are rising a bit in Europe and it’s anyone’s guess where this is heading. But certainly, it appears that many of us are done with the pandemic. Does this mean the boom in meal kits will fade? Will it turn out that they were just a pandemic […]
February 28, 2022 — “If you don’t know where you’re going, you’ll end up someplace else.” Yogi Berra had that right. So it’s good to start into OCW2022 by clearly looking ahead at the future for obesity care with six distinguished leaders from diverse backgrounds. In a wide-ranging discussion for OCW2022, they are looking forward to advances in science, […]
February 12, 2022 — To each his own – because truly, one size will never fit all. We can find no better illustration for this than the idea that perfectly healthy people might want to wear a continuous glucose monitors. And yet we have a crop of new tech startups that want to put these glucose monitors on all […]
February 9, 2022 — There’s a race heating up. It is a race to open the way for better obesity care and deliver better options. In this race, semaglutide (Wegovy™) has a head start. But a pack of other options are on the way. Yesterday in JAMA, results in a study of tirzepatide for treating type 2 diabetes tell […]
January 25, 2022 — The pandemic rearranged the landscape for many industries, and it certainly did that for the fitness industry. In 2019, it was a $97 billion industry. Then it shrank to $54 billion in 2021. Facilities closed and suddenly the big trends were fitness apps, home fitness, and outdoor workouts. Proving that luck matters, Peloton soared in […]
